This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,998 to Minutia Inc. to develop advanced stem cell-derived pancreatic islet cell technologies for treating type 1 diabetes. The key products and services to be delivered under this award include: Assessing the impact of genetically modifying stem cell-derived islet cells to be more...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to address barriers in pancreatic islet transplantation for treating type 1 diabetes. The $208,428 award will fund research to improve the survival and engraftment of stem cell-derived beta cells, as well as incorporate safety switches to allow for the clearance of any aberrant cells. The...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
The National Institutes of Health (NIH) Office of the Director awarded a $300,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Sanford Research, a non-profit biomedical research organization, for the project "ENGINEERING HUMAN T REGULATORY CELLS WITH CHIMERIC ANTIGEN RECEPTOR TARGETING NTPDASE3 ON THE SURFACE OF B CELLS FOR TYPE 1 DIABETES CONTROL". The project aims to create and validate a novel, antigen-specific cellular therapy for type 1 diabetes by...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $500,928 to Pupil Bio, Inc. to develop an early detection test for Type 1 Diabetes (T1D) using next-generation sequencing (NGS) analysis of B cell-specific methylation patterns in cell-free DNA (cfDNA). The key objectives are to: 1) Validate thousands of candidate methylation patterns...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to The Regents of the University of California, San Francisco (UCSF) to develop a stem cell-based multi-cellular platform that integrates diverse immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,232,846 to the Scripps Research Institute in La Jolla, CA to advance research on the mechanisms of beta cell death in type 1 diabetes. The key products and services to be delivered under this 2-year award include: 1) Building a vascularized micro-organ platform using induced...
This National Science Foundation (NSF) Division of Computer and Network Systems Project Grant award totaling $839,998 to Michigan State University supports the development of a novel wireless optoelectronic implant system for closed-loop control of bi-hormone (insulin and glucagon) secretion from genetically modified islet organoids. The goal is to create an implantable, wireless, and battery-free device that can precisely regulate hormone levels to manage type 1 diabetes. The project involves...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $990,990 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Integrated Medical Sensors Inc. (IMS), a minority-owned small disadvantaged business in Irvine, CA. The objective is to optimize the manufacturing and quality framework for IMS's CGM+ continuous glucose monitoring platform, which uses miniaturized semiconductor-based electrochemical sensors to measure...
This federal Project Grant award of $698,646, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to understand the functional and disease relevance of putative beta-cell subtypes in type 2 diabetes (T2D). The research project, led by the Van Andel Research Institute (VAI), will use novel single-cell epigenomic tools to determine the relationship between...
REAL-TIME INTRACELLULAR MONITORING OF MICRORNAS IN HUMAN STEM CELL-DERIVED INSULIN PRODUCING ORGANOIDS - PROJECT SUMMARY/ABSTRACT ASIDE FROM DAILY INSULIN THERAPY, INTRA-PORTAL HEPATIC TRANSPLANTATION OF CADAVERIC DONOR ISLETS IS THE ONLY OTHER RECOURSE FOR PATIENTS WITH TYPE 1 DIABETES (T1D) FOR LONG-TERM MANAGEMENT OF THIS DISEASE. EXOGENOUS ADMINISTRATION OF INSULIN DOES NOT REPLICATE WHAT THE ENDOGENOUS BETA CELL, AN EXQUISITE SENSOR AND REGULATOR OF CIRCULATING BLOOD GLUCOSE, ACCOMPLISHES SO ELEGANTLY. REPLACEMENT THERAPY CURRENTLY SUFFERS FROM LIMITED ACCESS TO PRIMARY ISLETS FOR GRAFTING, AND THE IMMEDIATE DAMAGE TO THE GRAFT POST-TRANSPLANTATION DUE TO INSUFFICIENT VASCULARIZATION AND HYPOXIA. FURTHERMORE, CURRENT TRANSPLANTATION SUCCESS IS VARIABLE, WITH C- PEPTIDE LEVELS AND GLUCOSE MEASUREMENTS USED AS READOUTS OF CELL FUNCTION, PARAMETERS THAT HAVE A DELAYED ONSET. REAL-TIME MONITORING OF CELL HEALTH AND FUNCTION IN RECIPIENTS HAS REMAINED ELUSIVE. HERE, WE DESCRIBE NOVEL SENSORS WITH THE CAPABILITY TO DETECT INTRACELLULARLY CHANGES FOR E.G. RESPONDING TO A STRESSFUL STIMULUS, AND TRANSMIT A MEASURABLE SIGNAL IN REAL-TIME TO COMMUNICATE SUCH SPECIFIC MOLECULAR CHANGES WITH HIGH SENSITIVITY. HUMAN STEM CELLS ARE DESCRIBED AS A LIMITLESS SOURCE OF CELLS FOR REPLACEMENT THERAPY, AND HAVE BEEN UNDER INTENSE SCRUTINY AND INVESTIGATION OVER THE LAST SEVERAL DECADES. RECENT SUCCESS IN GENERATING PANCREATIC CELLS INCLUDING THE INSULIN-PRODUCING BETA CELL FROM HUMAN STEM CELLS HERALDS A NEW ERA IN REGENERATIVE MEDICINE, SIMULTANEOUSLY REPRESENTING MATERIAL THAT SERVES AS A SURROGATE FOR CADAVERIC ISLETS, AND A PLATFORM TO DEVELOP TOOLS THAT CAN REPORT THE HEALTH OF CELL GRAFTS POST-TRANSPLANTATION, A TECHNOLOGY THAT IS MISSING FROM CURRENT METHODS TO EVALUATE CELL HEALTH. TO DEVELOP SUCH A DETECTION SYSTEM TO ASSESS VIABILITY AND HEALTH OF BETA CELL ORGANOIDS, WE HAVE ENGINEERED NANOPROBES THAT BIND MICRORNAS (MIRNAS) IN CELL EXTRACTS AND INTRACELLULARLY, AND SERVE AS A HOMING BEACON TO IDENTIFY ENDOGENOUS RNA SPECIES WITHOUT PRE-AMPLIFICATION. MICRORNAS ARE IMPORTANT REGULATORS OF GENE EXPRESSION AND ARE KNOWN TO BE DYSREGULATED IN DISEASE, SERVING AS UNIQUE DIAGNOSTIC MARKERS FOR SENSING CELL HEALTH. OUR NANOPROBES ARE SPECIFIC, SENSITIVE, AND CAN BE DETECTED IN VIVO IN ANIMAL MODELS. HERE, WE MERGE THESE TWO TECHNOLOGIES TO TACKLE THE CHALLENGE OF MONITORING TISSUE HEALTH IN GRAFT RECIPIENTS SUFFERING FROM T1D. BETA CELL CLUSTERS/ORGANOIDS THAT WE GENERATE IN A DISH WILL INCORPORATE SPECIFIC SENSORS THAT DETECT MICRORNA CHANGES TRIGGERED BY THE ONSET OF HYPOXIA. HYPOXIA IS A MAJOR ROADBLOCK FACING ISLET TRANSPLANTATION APPROACHES TODAY. OUR LONG-TERM GOAL IS TO DEVELOP TOOLS THAT CAN SENSE, IN VIVO, COMPROMISED GRAFT HEALTH LONG BEFORE SECONDARY READOUTS SUCH AS REDUCED C-PEPTIDE LEVELS AND DYSGLYCEMIA, AND IMPROVE TRANSPLANTATION SUCCESS FOR PATIENTS WITH T1D.